Skip to navigation Skip to content

Patriot News Organization

patriotnewsorganization.com

Primary Menu
  • Health News
  • Home
  • Corneal Disease
Study Estimates Incidence of Dupilumab-Related Conjunctivitis
Health News

Study Estimates Incidence of Dupilumab-Related Conjunctivitis

06/20/2021

One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. “About 4 years after dupilumab’s approval, we’re…

Read More
Aflibercept Won’t Help Vision in Early Diabetic Retinopathy
Health News

Aflibercept Won’t Help Vision in Early Diabetic Retinopathy

04/03/2021

Intravitreal injections with aflibercept (Eylea) don’t improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk for center-involved diabetic macular edema and proliferative diabetic retinopathy, however, said Adam R. Glassman, MS,…

Read More
Study investigates the prevalence of eye disease in adults with Down syndrome
Health News

Study investigates the prevalence of eye disease in adults with Down syndrome

03/11/2021

Drs. Dimitrios Karamichos and Melissa Petersen at The University of North Texas Health Science Center at Fort Worth, are teaming with DownSyndrome Achieves (DSA) Biobank in Ohio to find clues about Keratoconus Dystrophy. Their research will help better identify individuals…

Read More
Recent Posts
  • Special requirements for cleaning medical center windows
  • How to calculate a moving budget
  • UKHSA and ONS publish latest Winter CIS data
  • Exploring artificial general intelligence for radiation oncology
  • New study sheds light on the connection between the microbiome and kidney stones
Copyright © All rights reserved. 2025 Patriot News Organization.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok